



GOVERNMENT OF BERMUDA

---

**Registry General**

**Patent Application Advertisements**

PATENT AND DESIGN ACT 1930

**GOVERNMENT NOTICE NO.: 8**

Notice is hereby given that person who has grounds of Opposition to the registration of any of the Patent Applications advertised herein according to the Invention claimed under the heading "Patent Applications advertised before Registration" may within two months from the date of this publication, lodge with the Registrar, Notice of Opposition in writing in duplicate accompanied by a fee of \$45 payable either by cheque made payable to the Accountant General, by cash or by Revenue Stamp obtainable at the Office of the Accountant General.

Please further note that Patent Applications filed in Bermuda for registration are shown with the Official Number accompanied by letters BM. Patent applications registered in the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters UK. Patent Applications registered in the European Union designating the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters EP.

---

**PATENT APPLICATIONS ADVERTISED BEFORE REGISTRATION**

**Patent No. 739EP**

**Description: ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF**

On **5 August 2022**, **MEDIMMUNE LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **MEDIMMUNE LIMITED**, claims to be the Inventor or Proprietor of an invention: **ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

**Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## Patent No. 740EP

**Description: 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER**

On **12 August 2022**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention: : **8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## Patent No. 741EP

**Description: SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYR IDIN-2-YIL)BENZAMIDE**

On **19 August 2022**, **ACERTA PHARMA B.V.**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **ACERTA PHARMA B.V.**, claims to be the Inventor or Proprietor of an invention: **SOLID FORMS AND FORMULATIONS OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYR IDIN-2-YIL)BENZAMIDE**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ACERTA PHARMA B.V.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 742EP**

### **Description: METHODS FOR IMPROVING ASTHMA SYMPTOMS USING BENRALIZUMAB**

On **26 September 2022**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention: **METHODS FOR IMPROVING ASTHMA SYMPTOMS USING BENRALIZUMAB** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 743EP**

### **Description: POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS**

On **26 September 2022**, **ASTRAZENECA AB.**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **ASTRAZENECA AB** claims to be the Inventor or Proprietor of an invention: **POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 744EP**

### **Description: RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF**

On **4 November 2022**, **MEDIMMUNE LIMITED** delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **MEDIMMUNE LIMITED.**, claims to be the Inventor or Proprietor of an invention **RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 745EP**

### **Description: SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS**

On 4 November 2022, **AMYLIN PHARMACEUTICALS, LLC**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AMYLIN PHARMACEUTICALS, LLC**, claims to be the Inventor or Proprietor of an invention **SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AMYLIN PHARMACEUTICALS, LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**